A Cross-Sectional Study Evaluating The Prevalence Of Non-Alcoholic Fatty Liver Disease (NAFLD) In Patients With Inflammatory Bowel Disease (IBD) Receiving Anti-Tumor Necrosis Factor (anti-TNF) Therapy And The Clinical Variables Associated With Both Disorders.

Trial Profile

A Cross-Sectional Study Evaluating The Prevalence Of Non-Alcoholic Fatty Liver Disease (NAFLD) In Patients With Inflammatory Bowel Disease (IBD) Receiving Anti-Tumor Necrosis Factor (anti-TNF) Therapy And The Clinical Variables Associated With Both Disorders.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2017 New trial record
    • 09 May 2017 Results presented at the Digestive Disease Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top